Table 1.
Clinical characteristics at the initiation of lenvatinib (n = 140).
| Characteristic | Median (Range) or Patients, n |
|---|---|
| Age, range, y | 75 (46–90) |
| Sex (male/female), n | 123/17 |
| Weight (<60/≥60 kg), n | 58/82 |
| Performance status (0/1), n | 128/12 |
| Etiology (HBV/HCV/NBNC), n | 14/50/76 |
| Total bilirubin, range, mg/dL | 0.7 (0.3–2.4) |
| Albumin, range, g/dL | 3.8 (2.7–4.8) |
| Prothrombin activity, range, % | 90 (59–129) |
| Child–Pugh score (5/6/7), n | 89/42/9 |
| mALBI grade (1/2a/2b), n | 58/34/48 |
| Size of main tumor, range, mm | 26.0 (8.0–130.0) |
| Number of tumors (2–3/4–6//≥7), n | 39/45/56 |
| Relative tumor volume (<50/≥50%), n | 131/9 |
| Tumor morphology (SN type/non-SN type), n | 56/84 |
| Serum AFP value, range, ng/mL | 16.1 (0.9–84001.6) |
| Serum DCP value, range, mAU/mL | 175.5 (13.0–93112.0) |
| Up to seven criteria (in/out), n | 48/92 |
| History of systemic treatment (with/without), n | 22/118 |
| Number of previous TACE procedure beforelenvatinib (0/1-2//≥3), n | 37/40/63 |
| TACE-refractory or unsuitable(refractory/unsuitable/refractory plus unsuitable/without), n | 10/49/74/7 |
| Lenvatinib followed by TACE (with/without), n | 51/89 |
| Observation period, range, months | 17.7 (1.0–45.0) |
HBV—hepatitis B virus infection; HCV—hepatitis C virus infection; NBNC—non-B-non-C viral hepatitis; mALBI—modified albumin-bilirubin; SN—simple nodular; AFP—alpha-fetoprotein; DCP—des-γ-carboxy prothrombin; TACE—transarterial chemoembolization.